Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Shares Outstanding (2016 - 2025)

Haemonetics has reported Shares Outstanding over the past 16 years, most recently at $46.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $46.8 million for Q4 2025, down 6.78% from a year ago — trailing twelve months through Dec 2025 was $46.8 million (down 6.78% YoY), and the annual figure for FY2025 was $48.2 million, down 5.06%.
  • Shares Outstanding for Q4 2025 was $46.8 million at Haemonetics, roughly flat from $46.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for HAE hit a ceiling of $51.3 million in Q3 2022 and a floor of $46.7 million in Q3 2025.
  • Median Shares Outstanding over the past 5 years was $50.7 million (2023), compared with a mean of $50.1 million.
  • Biggest five-year swings in Shares Outstanding: increased 1.08% in 2021 and later dropped 7.21% in 2025.
  • Haemonetics' Shares Outstanding stood at $51.1 million in 2021, then dropped by 1.21% to $50.4 million in 2022, then rose by 0.68% to $50.8 million in 2023, then fell by 1.08% to $50.2 million in 2024, then fell by 6.78% to $46.8 million in 2025.
  • The last three reported values for Shares Outstanding were $46.8 million (Q4 2025), $46.7 million (Q3 2025), and $48.2 million (Q2 2025) per Business Quant data.